Capromorelin Tartrate is an orally active, potent growth hormone secretagogue receptor (GHSR) agonist, with K_i of 7 nM for hGHS-R1a. IC50 & Target: Ki: 7 nM (hGHS-R1a)^[2] In Vitro: Capromorelin stimulates GH release in rat pituitary cell cultures with EC₅₀ of 3 nM^[2]. In Vivo: Dogs receiving capromorelin (30 mg/mL) have food consumption that is significantly greater than dogs treated with placebo. All dogs in the capromorelin group gain weight by 0.52 kg, more than that of placebo group^[1]. Capromorelin shows enhanced intestinal absorption in rodent models and exhibits superior pharmacokinetic properties, including high bioavailabilities in two animal species [F(rat)=65%, F(dog)=44%]^[2]. Capromorelin stimulates GH release in anesthesized rat model, with ED₅₀ of 0.05 mg/kg iv^[2].